Samyag

Corporate Actions

Back

Zydus Life gets USFDA nod for Verapamil ER tablets

25-Nov-25 16:32 Hrs IST

The product is the generic equivalent of Calan SR Extended-Release Tablets.

The medication is used for the management of high blood pressure, helping reduce the risk of cardiovascular complications such as strokes and heart attacks.

Zydus will manufacture the approved product at its facility in Baddi, Himachal Pradesh.

According to IQVIA MAT September 2025 data, Verapamil Hydrochloride ER Tablets recorded annual sales of $ 24.5 million in the US market.

With this approval, Zydus' cumulative tally rises to 428 approvals. The group has filed 487 ANDAs since it began the filing process in FY 2003'04.

The Zydus Group with an overarching purpose of empowering people with freedom to live healthier and more fulfilled lives, is an innovative, global life-sciences company that discovers, develops, manufactures, and markets a broad range of healthcare therapies. The group employs over 27000 people worldwide and is driven by its mission to unlock new possibilities in lifesciences through quality healthcare solutions that impact lives.

Zydus Lifesciences reported 38.12% jump in consolidated net profit to Rs 1,258.60 crore in Q2 FY26, compared with Rs 911.2 crore posted in Q2 FY25. Revenue from operations increased 18.07% year on year (YoY) to Rs 6,037.9 crore in Q2 FY26.

The counter rose 0.15% to close at Rs 928 on the BSE.

Powered by Capital Market - Live News

Attention Investors: Stock Brokers can accept securities as margin from clients only by way of pledge in the depository system w.e.f. September 1, 2020. || Update your mobile number & email Id with your stock broker/depository participant and receive OTP directly from depository on your email id and/or mobile number to create pledge. || Pay 20% upfront margin of the transaction value to trade in cash market segment. || Investors may please refer to the Exchange's Frequently Asked Questions (FAQs) issued vide circular reference NSE/INSP/45191 dated July 31, 2020 and NSE/INSP/45534 dated August 31, 2020 and other guidelines issued from time to time in this regard. || Check your Securities /MF/ Bonds in the consolidated account statement issued by NSDL/CDSL every month.|| KYC is one time exercise while dealing in securities markets - once KYC is done through a SEBI registered intermediary (broker, DP, Mutual Fund etc.), you need not undergo the same process again when you approach another intermediary.|| No need to issue cheques by investors while subscribing to IPO. Just write the bank account number and sign in the application form to authorise your bank to make payment in case of allotment. No worries for refund as the money remains in investor's account.